[go: up one dir, main page]

ATE395101T1 - Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel - Google Patents

Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel

Info

Publication number
ATE395101T1
ATE395101T1 AT04727664T AT04727664T ATE395101T1 AT E395101 T1 ATE395101 T1 AT E395101T1 AT 04727664 T AT04727664 T AT 04727664T AT 04727664 T AT04727664 T AT 04727664T AT E395101 T1 ATE395101 T1 AT E395101T1
Authority
AT
Austria
Prior art keywords
polypeptides
proteins
pharmaceutical composition
polypeptide
protein
Prior art date
Application number
AT04727664T
Other languages
English (en)
Inventor
Moshe Baru
Lea Carmel-Goren
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Application granted granted Critical
Publication of ATE395101T1 publication Critical patent/ATE395101T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04727664T 2003-04-15 2004-04-15 Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel ATE395101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46270103P 2003-04-15 2003-04-15

Publications (1)

Publication Number Publication Date
ATE395101T1 true ATE395101T1 (de) 2008-05-15

Family

ID=33299976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727664T ATE395101T1 (de) 2003-04-15 2004-04-15 Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel

Country Status (15)

Country Link
US (1) US20070167359A1 (de)
EP (1) EP1633440B1 (de)
JP (1) JP2006523683A (de)
CN (1) CN1774281B (de)
AT (1) ATE395101T1 (de)
AU (1) AU2004229253B2 (de)
BR (1) BRPI0409424B8 (de)
CA (1) CA2522179C (de)
DE (1) DE602004013769D1 (de)
DK (1) DK1633440T3 (de)
ES (1) ES2307009T3 (de)
MX (1) MXPA05010926A (de)
PL (1) PL1633440T3 (de)
PT (1) PT1633440E (de)
WO (1) WO2004091723A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (de) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
US20220347113A1 (en) * 2019-11-07 2022-11-03 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
CN115521603A (zh) * 2021-06-24 2022-12-27 复旦大学 一种可原位相转变形成凝胶的组合物及其用途
US20240058419A1 (en) * 2022-08-22 2024-02-22 Buddhist Tzu Chi Medical Foundation Method for treating optic neuropathy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995021629A1 (en) * 1994-02-08 1995-08-17 Amgen Inc. Oral delivery of chemically modified proteins
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
DE69922189T2 (de) * 1998-04-27 2005-11-10 Opperbas Holding B.V. Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
JP2003505401A (ja) * 1999-07-14 2003-02-12 アルザ・コーポレーション 中性リポポリマーとそれを含有するリポソーム組成物
AU2001238469C1 (en) * 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
WO2002086117A1 (en) * 2001-04-20 2002-10-31 The University Of Vermont Compositions and methods to control bleeding
EP1461014B1 (de) * 2001-12-04 2021-07-14 Ben Gurion University Of The Negev Research And Development Authority Amphiphile verbindungen und vesikel/liposome für das organspezifische arzneimittel-targeting

Also Published As

Publication number Publication date
BRPI0409424A (pt) 2006-04-25
CA2522179A1 (en) 2004-10-28
BRPI0409424B8 (pt) 2021-05-25
JP2006523683A (ja) 2006-10-19
CA2522179C (en) 2012-02-14
CN1774281A (zh) 2006-05-17
DK1633440T3 (da) 2008-09-08
PL1633440T3 (pl) 2008-12-31
AU2004229253B2 (en) 2009-11-05
ES2307009T3 (es) 2008-11-16
BRPI0409424B1 (pt) 2018-05-02
PT1633440E (pt) 2008-08-25
US20070167359A1 (en) 2007-07-19
EP1633440B1 (de) 2008-05-14
WO2004091723A1 (en) 2004-10-28
EP1633440A1 (de) 2006-03-15
MXPA05010926A (es) 2005-11-25
AU2004229253A1 (en) 2004-10-28
CN1774281B (zh) 2010-10-13
DE602004013769D1 (de) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE450548T1 (de) Rgd-angereicherte gelatineähnliche proteine mit verstärkter zellbindung
DE69922189D1 (de) Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
AU6819294A (en) Oral drug delivery compositions and methods
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
DK1137400T3 (da) Præparater indeholdende et peptid og polymælkesyre-glycolsyre egnet til fremstilling af subkutane implantater med en forlænget frigivelsesperiode
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
DE69426019D1 (de) Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
CA2499014A1 (en) Lactoferrin compositions and methods of wound treatment
JP2006131648A (ja) コラーゲンベースの注入可能な薬剤送達製剤およびその使用
EP2711025A3 (de) Selbstangeordnete Peptide mit Modifikationen und Verwendungsverfahren dafür
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
ATE191615T1 (de) Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung
ATE395101T1 (de) Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
DK0523330T3 (da) Implanterbare sammensætninger indeholdende et biologisk aktivt protein, peptid eller polypeptid
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
Sutherland et al. Biocompatibility and immunogenic response to recombinant honeybee silk material
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
Ali et al. Marine collagen: promising biomaterial in delivery of therapeutics for cancer therapy
KR102218427B1 (ko) 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
EP1862170A1 (de) Proteinformulierung
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633440

Country of ref document: EP

REN Ceased due to non-payment of the annual fee